Although the pharmaceutical market in 2016 is turbulent, there are also remarkable places. The war in 2017 has begun, and many pharmaceutical companies have invested in the research and development and production of innovative drugs, striving to take the lead in the new round of market competition. So, in the pharmaceutical market, which drugs will frequently become the headlines of the pharmaceutical industry? FirstWord website has combed this.

Dupixent

The approval deadline for the Dupixent(Dupilumab) of Regeneron and Sanofi is the end of March. The drug is used to treat moderate to severe allergic dermatitis. Its Ocrevus with Roche was originally expected to be on the market in 2016. Analysts predict that Dupixent will generate more than $4 billion in sales in 2022.

Ocrevus

Ocrevus was delayed by the US FDA. It is Roche's new drug for the treatment of multiple sclerosis (MS). It was originally expected to be launched in December 2016, which is one of the reasons for the decline in the number of new drug approvals in 2016. It is expected to be approved within the next three months. The approval delay is due to Roche's submission of new production data, not Ocrevus safety or effectiveness issues. The drug is used to treat relapsing-remitting MS, and with the release of positive phase III data, it will be the first drug to treat primary progressive MS.

Praluent/Repaltha

PCSK9 inhibitors Praluent and Repatha, sold by Regenera/Sanofi and Amgen (Amgen) respectively, have appeared many times in the annual sales star forecast list, but so far, the results of the two have not been satisfactory, which also shows the serious attitude of the payer towards this kind of drug. However, aggressive cardiovascular research data, to be published later in 2017, will hopefully reduce barriers to its use and expand its use.

Spinraza

The FDA approved Biogen and Ionis Pharmaceuticals Spinraza for the treatment of spinal muscular atrophy (SMA) in December 2016, about four months ahead of schedule. Spinraza, one of the most high-profile new drugs of 2017, was priced much higher than expected, encouraged by the FDA's rapid approval and the Spinraza's therapeutic role in all subtypes of Spinraza, a bold decision that has been debated in the United States.

Durvalumab

In 2017, PD-(L)1 inhibitors will continue to receive attention in the field of tumor immunotherapy, especially in the context of the increasing use of Merck's Keytruda for first-line treatment of patients with early-stage non-small cell lung cancer (NSCLC). At the same time, AstraZeneca (AstraZeneca) durvalumab combined with CTLA-4 inhibitor tremelimumab for early NSCLC MYSTIC study will attract more attention. MYSTIC study results are expected to be released in the first half of 2017. If the results are positive, AstraZeneca will occupy a leading position in the tumor immunotherapy market. If the results are negative, it will make people doubt the company's prospects in this market.

Keytruda/Tecentriq/Opdivo

Merck and Roche will release the first batch of phase III data of PD-(L)1 inhibitor combined chemotherapy for early non-small cell lung cancer at the end of 2017. Through these data, we can see more clearly how to divide the market of this special disease through different treatment schemes in the next few years. Bristol-Myers Squibb (Bristol-MyersSquibb) also revealed that it may submit an application for PD-1 inhibitors in combination with CTLA-4 inhibitors (I. e. Opdivo and Yervoy) for the treatment of non-small cell lung cancer by the end of 2017.

KTE-C19/CTL019

CAR-T therapies will continue to be in focus in 2017 as KitePharma and Novartis (Novartis) filed applications with the FDA for KTE-C19 (for relapsed/refractory aggressive B- cell non-Hodgkin's lymphoma) and CTL019 (for pediatric and younger patients with relapsed/refractory B- cell acute lymphoblastic leukemia), respectively. The FDA's assessment of this cutting-edge treatment will be influenced by the recent death of a patient from JunoTherapeutics, one of the competitors in the CAR-T field.

Rubraca/niraparib

In 2017, the number of listed PARP inhibitors will increase to three: the FDA approved the ClovisOncology Rubraca in December 2016 for the treatment of ovarian cancer with stage III BRCA mutations; Tesaro has been looking forward to niraparib approval for the second-line treatment of ovarian cancer unrelated to biomarker status. In December 2016, Tesaro confirmed that its application was under priority review, indicating that the FDA would make an approval decision by the end of June this year. Supported by the positive data in the later study, AstraZeneca is already promoting PARP inhibitors Lynparza 3-line treatment for ovarian cancer.

Nuplazid

Acadia Pharmaceuticals, which was approved in 2016 for the treatment of hallucinations and delusions in Parkinson's patients, seems to be Nuplazid promising for the treatment of Alzheimer's disease. At the end of 2016, the company reported early positive data from a phase II study. Because Acadia is often used as a potential acquisition target for large pharmaceutical or biotech companies, the data from this study and other trials, including Nuplazid potential for Alzheimer's disease agitation, are eagerly awaited.

Epidiolex

GW Pharmaceuticals may also be acquired, mainly due to the success of its flagship product Epidiolex in clinical studies of two rare epilepsy disorders, Dravet syndrome and Lennox-Gastaut syndrome (LGS). Stage III data for Dravet syndrome, published in December 2016, were lower than expected, showing that Epidiolex reduced the total number of seizures but did not significantly reduce them compared with baseline. However, expectations for the drug remain high. In 2017, some of the previous public data will be fully published, as well as early results for other indications, and GW Pharmaceuticals is preparing to apply for Epidiolex for the treatment of LGS and Dravet syndrome in the United States and the European Union at the same time.

Verube cestat

Phase III data on Mercadon's BACE inhibitor verubecestat will be released in mid -2017 as research into Alzheimer's disease-improving drugs continues. While expectations for this type of drug are still relatively high, verubecestat are also considered high risk because patients enrolled in the pivotal phase EPOCH study were not pre-screened for beta-amyloid plaque levels. The data from this drug will have a significant impact on the enthusiasm for the development of BACE inhibitors.

Bolt

In the next few years, the market threat of biosims to original drugs in the field of oncology therapy will gradually intensify, and Roche urgently needs to Herceptin positive results from studies with Perjeta for HER2-positive breast cancer (from the APHINITY trial), and shareholders have higher expectations for this. In the treatment of metastatic breast cancer, the combination of Herceptin and Perjeta has considerably improved outcomes.